Skip to main content
. 2023 Jun 29;12(13):e029071. doi: 10.1161/JAHA.122.029071

Figure 4. Prevalence of most frequent contraindications and cautions to life‐saving therapies in heart failure with reduced ejection fraction.

Figure 4

ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; AV, atrioventricular; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; and SGLT2i, sodium‐glucose cotransporter 2 inhibitor.